Lenograstim is a medication indicated for the treatment of neutropenia, a condition characterized by a low count of neutrophils (a type of white blood cell) in the body. Neutropenia can occur as a side effect of chemotherapy, which can weaken the immune system, making the body more susceptible to infections. Lenograstim helps stimulate the production of neutrophils, thereby reducing the risk of infections in individuals undergoing cancer treatment or bone marrow transplantation.
Reduction In The Duration Of Neutropenia Following Bone-marrow Transplantation Or Peripheral Stem Cells Transplantation For Non-myeloid Malignancy:
By Sc Inj Or Iv Infusion:
Adult: 150 Mcg/m2 Daily Until Neutrophil Count Stable In an Acceptable Range (max. 28 Days), To Be Started The Day After Transplantation.
Reduction In The Duration Of Neutropenia Following Treatment With Cytotoxic Chemotherapy Associated With A Febrile Neutropenia:
By Sc Inj:
Adult: 150 Mcg/m2 Daily Until Neutrophil Countstable In Acceptable Range (max. 28 Days), To Be Started On The Day After Completion Of Chemotherapy
Mobilization Of Peripheral Blood Progenitor Cells For Harvesting And Subsequent Infusion:
By Sc Inj:
Adult: 10 Mcg/kg Daily For 4-6 Days
Mobilisation Of Peripheral Blood Progenitor Cells, Used Following Adjunctive Myelosuppressive Chemotherapy:
By Sc Inj:
Adult: 150 Mcg/m2 Daily Until Neutrophil Count Stable In Acceptable Range, To Be Started 1-5 Days After Completion Of Chemotherapy,(for Treatment Of Leucopheresis, Consult Product Literature)
Content
Inj 263 Mcg: Lenograstim 263 Mcg (33.6 Million Units); Powder In Vials And Water For Injection In Amp.
Pregnancy
Risk Cannot Be Ruled Out.
Stability
Recombinant G-csf (recombinant Human Granulocyte-colony Stimulating Factor)
Contra Indications
Severe Congenital Neutropenia (kostmann's Syndrome) With Abnormal Cytogenetics.
Precautions
Severe Congenital Neutropenia (kostmann's Syndrome) With Abnormal Cytogenetics.
Lactation
Caution Advised or Effect Undetermined.
Side Effects
Mucositis
Splenic Rupture
Toxic Epidermal Necrolysis
Musculoskeletal Pain
Transient Hypoten-sion
Disturbances In Liver Enzymes And Serum Uric Acid; Thrombocytopenia; Urinary Abnormalities Including Dysuria; Allergic Reactions (more Common After Intravenous Infusion)
Proteinuria
Haematuria
And Transient Decrease In Blood Glucose; On Long-term Use Cutaneous Vasculitis